Limited synchronous hepatic resection does not compromise peri‐operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Issue 4 (9th February 2017)

• Record Type: Journal Article
• Authors: Saxena, Akshat; Valle, Sarah J.; Liauw, Winston; Morris, David L.
• Is Part Of: Journal of surgical oncology. Volume 115:Issue 4(2017)
• Page Start: 417
• Page End: 424
• Publication Date: 2017-02-09
• Subjects: cytoreductive -- hepatic resection -- hyperthermic -- intraperitoneal -- morbidity -- mortality -- survival; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.24543
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract : INTRODUCTION: There is uncertainty about whether hepatic resection (HR) combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective. METHODS: Nine hundred and thirty‐five consecutive CRS/HIPEC procedures were performed between 1996 and 2016 of which 132(14%) involved concomitant HR. Peri‐operative complications were graded according to the Clavien‐Dindo Classification. The association of concomitant HR with 19 peri‐operative outcomes and overall survival (OS) was assessed using univariate and multivariate analyses. RESULTS: Patients undergoing HR had a lower peritoneal disease burden (peritoneal cancer index <17) (46 vs 29%, P < 0.001) and underwent a shorter operation (<9 h) (53 vs 42%, P = 0.019). After accounting for confounding factors, HR was not associated with in‐hospital mortality (Relative risk [RR], 2.47; 95% confidence interval [CI], 0.52‐11.77; P = 0.577) or grade III/IV morbidity (RR, 1.18; 95%CI, 0.74‐1.90; P = 0.488). Moreover, HR was not associated with an increased risk of other complications on univariate or multivariate analysis. Median OS for all colorectal cancer patients was 32.3 month with resected HM versus 30.5 months without HM ( P = 0.587). CONCLUSION: Given prudent patient selection, concomitant HR does not compromise peri‐operative outcomes or survival after CRS/HIPEC.